AI Article Synopsis
Article Abstract
Background: Recently, as a possible therapy resolving solution, pentadecapeptide BPC 157 therapy, has been used in alleviating various vascular occlusion disturbances. BPC 157 was previously reviewed as novel mediator of Robert cytoprotection and endothelium protection in the stomach, and gut-brain axis, beneficial therapy in gastrointestinal tract, with particular reference to vascular recruitment, ulcerative colitis and tumor cachexia, and other tissues healing. Here we raised new hypothesis about BPC 157 therapy in the Budd-Chiari syndrome in rats, rapid bypassing of the suprahepatic inferior caval vein occlusion, and rats recovery with the active and effective pharmacotherapy treatment.
Aim: To investigate Budd-Chiari syndrome model (inferior caval vein suprahepatic occlusion) resolution, since BPC 157 resolves various rat vascular occlusion.
Methods: We assessed the activated bypassing pathways between the inferior and superior caval veins and portocaval shunt, counteracted caval/portal hypertension, aortal hypotension, venous/arterial thrombosis, electrocardiogram disturbances, liver and gastrointestinal lesions (., stomach and duodenum hemorrhages, in particular, congestion). Rats with suprahepatic occlusion of the inferior vena cava by ligation were medicated at 1 min, 15 min, 24 h, or 48 h post-ligation. Medication consisted of 10 µg/kg BPC 157, 10 ng BPC 157 or 5 mL/kg saline, administered once as an abdominal bath or intragastric application. Gross and microscopic observations were made, in addition to assessments of electrical activity of the heart (electrocardiogram), portal and caval hypertension, aortal hypotension, thrombosis, hepatomegaly, splenomegaly and venography. Furthermore, levels of nitric oxide, malondialdehyde in the liver and serum enzymes were determined.
Results: BPC 157 counteracted increased P wave amplitude, tachycardia and ST-elevation, ., right heart failure from acute thrombotic coronary occlusion. The bypassing pathway of the inferior vena cava-azygos (hemiazygos) vein-superior vena cava and portocaval shunt occurred rapidly. Even with severe caval ˃ portal hypertension, BPC 157 antagonized portal and caval hypertension and aortal hypotension, and also reduced refractory ascites. Thrombosis of portal vein tributaries, inferior vena cava, and hepatic and coronary arteries was attenuated. In addition, there was reduced pathology of the lungs (severe capillary congestion) and liver (dilated central veins and terminal portal venules), decreased intestine hemorrhagic lesions (substantial capillary congestion, submucosal edema and architecture loss), and increased liver and spleen weight. During the period of ligation, nitric oxide- and malondialdehyde-levels in the liver remained within normal healthy values, and increases in serum enzymes were markedly reduced.
Conclusion: BPC 157 counteracts Budd Chiari syndrome in rats.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7093306 | PMC |
| http://dx.doi.org/10.4291/wjgp.v11.i1.1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.
Altern Ther Health Med
October 2024
Article Synopsis
- Moderate to severe interstitial cystitis (bladder pain syndrome) currently lacks effective long-term treatments, with pentosan polysulfate having limitations and potential side effects.
- A study involving 12 women aged 39-76 tested BPC-157, an unapproved peptide, via bladder injections to evaluate its safety and efficacy for interstitial cystitis.
- Results showed that 10 out of 12 patients experienced complete symptom resolution after one injection, while the remaining 2 reported significant improvement, marking the first positive report on BPC-157 for this condition.
Injectable Therapeutic Peptides-An Adjunct to Regenerative Medicine and Sports Performance?
Arthroscopy
September 2024
10th Medical Group, US Air Force Academy, San Antonio, Colorado, U.S.A.
High-level athletes and bodybuilders are constantly seeking novel therapies to enhance recovery and expedite return from injury-injectable peptides are a new and trending therapy that may be the wave of the future in the realm of regenerative medicine research in treating joint injuries and osteoarthritis. Very early in vivo research on pharmacokinetics indicates the possibility that body protection compound 157 (BPC-157) is at the forefront of therapeutic peptides, with early demonstrations of this experimental peptide optimizing endurance training, metabolism, recovery, and tissue repair. Although unregulated and yet readily available for purchase over the internet, there is scarce orthopaedic literature investigating the clinical use and outcomes of such therapeutic peptides in tendon, muscle, and cartilage injury.
View Article and Find Full Text PDFStable Gastric Pentadecapeptide BPC 157 and Intestinal Anastomoses Therapy in Rats-A Review.
Pharmaceuticals (Basel)
August 2024
Clinic of General and Abdominal Surgery, Clinical Center University of Sarajevo, 71000 Sarajevo, Bosnia and Herzegovina.
By introducing the healing of many distinctive anastomoses by BPC 157 therapy, this review practically deals with the concept of the resection and reconnection of the hollow parts of the gastrointestinal tract as one of the cornerstones of visceral surgery. In principle, the healing of quite distinctive anastomoses itself speaks for applied BPC 157 therapy, in particular, as a way in which the therapy of anastomoses can be successfully approached and carried out. Some of the anastomoses implicated were esophagogastric, colocolonic, jejunoileal, and ileoileal anastomoses, along with concomitant disturbances, such as esophagitis, sphincter dysfunction, failed intestinal adaptation, colitis, short bowel syndrome, major vessel occlusion, NO-system, and prostaglandins-system dysfunction, which were accordingly counteracted as well, and, finally, findings concerning other anastomoses healing (i.
View Article and Find Full Text PDFNew studies with stable gastric pentadecapeptide protecting gastrointestinal tract. significance of counteraction of vascular and multiorgan failure of occlusion/occlusion-like syndrome in cytoprotection/organoprotection.
Inflammopharmacology
October 2024
Department of Pathology, School of Medicine, University of Zagreb, 10000, Zagreb, Croatia.
Article Synopsis
- * Clinical evidence supports BPC 157’s effectiveness in treating various conditions, including ulcerative colitis, with no side effects reported, and it demonstrates a capacity for tissue regeneration across multiple systems such as muscles, tendons, and the heart.
- * The review discusses BPC 157's role in counteracting severe complications from major vessel failures and various organ system disturbances, emphasizing its use in conditions linked to alcohol-induced stomach lesions and overall vascular recovery.
The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity.
Pharmaceuticals (Basel)
April 2024
Department of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
We highlight the particular aspects of the stable gastric pentadecapeptide BPC 157 pleiotropic beneficial activity (not destroyed in human gastric juice, native and stable in human gastric juice, as a cytoprotection mediator holds a response specifically related to preventing or recovering damage as such) and its possible relations with neurotransmitter activity. We attempt to resolve the shortage of the pleiotropic beneficial effects of BPC 157, given the general standard neurotransmitter criteria, in classic terms. We substitute the lack of direct conclusive evidence (i.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!